Telix制药(Telix Pharmaceuticals,TLPPF)报告第三季度营收同比增长53%,并将2025财年营收指引上调至8-8.2亿美元。公司计划增加研发投入以支持扩展中的临床管线,彰显其对医药领域创新的承诺。

本文地址: http://www.jiaotongmi.com/article/19026.html
文章来源:admin
版权声明:除非特别标注,否则均为本站原创文章,转载时请以链接形式注明文章出处。
2025-11-09admin
2025-11-08admin
2025-11-07admin
2025-11-06admin
2025-11-05admin
2025-11-04admin
2025-11-03admin
2025-10-29admin
2025-10-29admin
2025-10-29admin
2025-09-08admin
2025-09-08admin
2025-09-13admin
2025-09-17admin
2025-09-17admin
2025-09-08admin
2025-09-09admin
2025-09-09admin
2025-09-13admin
2025-09-11admin
2025-10-29admin
2025-11-06admin
2025-10-29admin
2025-10-29admin
2025-10-29admin
2025-10-29admin
2025-10-29admin
2025-10-29admin
2025-10-29admin
2025-10-29admin
扫码二维码
获取最新动态
